Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716169 · ClinicalTrials.gov registry record · NA
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01716169: Completed NA study, sponsored by Stanford University.
NCT01716169 is a NA study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716169, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of Helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (RDEB) patients. Helicoll will be compared to standard wound dressings.
Interventions
- DEVICE Helicoll
- DEVICE Standard of Care Dressings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716169
The ClinicalTrials.gov registry entry for NCT01716169 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Helicoll is the first listed.
NCT01716169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716169 about?
NCT01716169 is a clinical study titled "Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care". The purpose of this study is to test the effectiveness of Helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (RDEB) patients. Helicoll will be compared to standard wound dressings.
What is the current status of trial NCT01716169?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01716169?
The interventions under investigation include: Helicoll (DEVICE), Standard of Care Dressings (DEVICE).
Who is sponsoring clinical trial NCT01716169?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.